Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.
Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.
Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology. A Phase 1 clinical trial launched in October 2006 in the US indicated that the vaccine candidate is safe in healthy adults. A second study, currently in progress in healthy adults in South Africa, appears to be showing safety, tolerability, and immunogenicity of AERAS-402.
The main parameters under examination in the St. Louis study will be the immunogenicity and safety of BCG prime followed by two AERAS-402 boost doses administered at three to six month intervals after BCG in healthy adults.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.